Sastokas, A. | Search bioRxiv

bioRxiv2025

Massively parallel evolution reveals a biophysical scaling law between cell size and internal cell density

Using a massively parallel evolution platform, we selected Saccharomyces cerevisiae for increased cell size to test how cellular architecture adapts to biophysical constraints. As cells evolved larger size, they became less spherical and showed reduced carrying capacity without changes in maximum growth rate. Optical diffraction tomography revealed that individual cells with greater volume consistently exhibited lower internal density, a relationship that persisted across replicate populations and evolved isolates. The largest cells often contained enlarged vacuoles, suggesting that vacuole expansion may sometimes contribute to reduced density. Extending this analysis beyond yeast, 68 species spanning major phylogenetic clades also demonstrate a negative scaling between cell density and cell size. Together, these results suggest that decreased internal density is a conserved consequence of increasing cell size, revealing a fundamental cellular trade-off between volume expansion and material concentration.

biophysics↗

bioRxiv2023

Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains

There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into 6 classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, while others do. And some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings may yet empower multidrug strategies that leverage tradeoffs to combat resistance. More generally speaking, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation.

evolutionary biology↗